Constellation is locked into their stock....They cannot sell any stock until the price moves way way beyond any price that we will see this year. They also hold millions of shares of unregistered stock that cannot be sold at any price. Only an idiot would sell here and if done, that person should not even be a holder of TCLN. Keep in mind we are dealing with penny stock investors here. Many will sell for a few hundred dollar profit.

Two issues there ....A high growth rate stock ,, with a profit yet ,,, deserves a much higher PE than 12....Could be 30 or 40. As for the profit potential ..This company would be operating with a relatively small expense ratio compared to the revenue rate per Hospital ,,,,given some of the potenial numbers given out by Constellation. Keep in mind this company sells a Software Application Package.It is a finished product that is sold over and over again. Maintenance is a cost paid for by the user. Quture also has a huge benefit given the partnership with Intersystems in marketing to it's customer base...80% of the hospitals out there.

Some very good news. The life blood of Bulova is a credit line ...As much as possible to allow manufacturing to build products....The Army/Navy pays up long after Bulova spends the money on production.Another 4M dollars can fund a lot of business.

There is a huge number of people who have bought into this stock, but they are not into the posting on the board or for that matter reading any boards .....That will come after the stock takes off when that crowd jumps on board IMO ....This stock has gone thru quiet accumulation over the past months ...It may get very busy on this board yet ....The Yahoo board is absolutely quiet right now..

Not sure what you're talking about .....But Bulova did have a 'contract assembly' business but the bank that held it's credit line,,, some 6 or 7M ,, got taken over and that credit line was lost. Despite having many millions in customers business ,,it could not be financed. That division,,BT Manufacturing, had to be sold. BTLV was never in the food or medical business .....Except for making circuit boards for Thoratec ,,, maker of the heart pump that went into Cheney and 10,000 other heart patients.

Actually Bulova was included in over 500M in contracts....But this comes with other companies included ...All get the business...But Bulova is limited to the amount of business it can finance on its credit line and cash on hand. As cash and credit line build total business will improve. I've been told there is a lot of credit at 18% or more ....but you can't make money with those rates.

Two problems ,,,The bulk of past contracts require many millions in working capital,,,a credit line ,, to finance the workflow ,,parts, labor and capex ...That is very hard to come by at 12% or below (where Bulova can still make a profit) As near as I can tell they have only 5 to 7 million (The Gov pays you long after you spend your money to make the stuff) ...The Euro work/contracts for the most part do not require cash up front as most are management contracts ...middlemen in the deal(half now, half when complete) ..and will pay up over time as will the US business while the company builds it's own cash.

Until Bulova becomes cash flow positive expect more stock to pay the bills ....Nobody, banks or investing houses, is going to give Bulova money to run the business every month....The bet here is the Contracts get the company there ,,,The Army contracts, Navy contract, All the European contracts...It's taking too much time to get there but that's why this stock is like a lottery ticket...selling for almost nothing. If you want a better bet on a stock buy a listed stock ,,,APPL ,,Facebook,,etc

It tells me they will get their first paying customer very soon, thus validating the business plan and the software product. This is an impressive company for a pink sheet listing.

These execs own a ton of shares ,,,an RS would hurt them too if done at the wrong time. BLTV must be profitable ,,, Net Profitable,,, first before any RS is done. Gurba feels the stock should be worth .25 a share ...I'll take that and he would too. The only reason for an RS would be to get on the AMEX if profitable ...That could work.

BLVT is being featured again on the 'Green Baron Report' today ....to all there members. BTW their is an audio interview with Steve Gurba on their website from last Nov. ..a good one IMO. .....Equiti-Trend, their PR Co....says news is coming ,,,also Q2's 10Q is coming due May 15th

tracker, You were correct about the obvious ,,, A pinksheet company with low revenue and no profit and the the stock price action to reflect that fact ....Pat yourself on the back....Only an idiot will think he's smart by trumpeting the 'facts'...
The play on Bulova has always been,,can Gurba get this company on a growth path...That takes time and is still playing out as we speak ...Only the patient belong on this board ,,,K

A lot .....Due to the fact that Quture did a reverse split into a shell OTC/BB company called TCLN (due to chg soon)to go public. All the value came from Quture, Hence those owners deserved a majority of the outstanding stock split post merger....Over 2B shares. Keep in mind all those insider holdings are tied up for 20yrs for the most part .....Meaning IMO, Quture will be sold to a larger company long before then.

...DAD .....The reason for the large insider position is the way the reverse merger was structured to go public. IMO, Basically Quture came into the deal with all the value and the old TCLN shell owners(10% of the shares maybe) brought almost no value to the deal except a cheaper way to go public. Quture execs taking restricted shares is fantastic for the public stock buyer ...for obvious reasons...But it also tells me the executive team is here to stay until the job gets done and will eventually sell Quture to a much bigger company within 2 or 3 years...IMO

Mastercard and Visa were already in settlement talks in 2010 ....No cash amount could be agreed to by SMME and the card companies. So you already know the card companies knew they were in trouble on this patent case. Now after the card companies losing this appeal, expect the settlement talks to start up again. Contact cards are nearly to total business done in the US....Since SMME's CEO owns most of the stock, Visa or Mastercard cannot just buy the company without meeting Colin Hendrick's price.

From the 10K ....NOTE
CEO Tim Carnihan treats himself really well as the Stockholders get the shaft ....
His salary 191,679
His bonus 358,334

For a total of $550,013 ....this on total company revenue of less than 2M for the year.

I do not think CYIO shareholders will ever make money in the future. Carnahan has allways refused to talk with stockerholders ...I tried. Forget emailing ...He now refuses to talk with Rockport Equity ,,,the IR group...Even the few PR's released in the past rarely made sense ... Carnahan is running Cyios as his private company as he did from 1994 to 2005 before going public ,,,Draining all the cash by yearend as his Pay.

And add to that the 'Addressable Market' @ 500M ....As Quture PR's any portion of that revenue this stock story becomes a fact of life. There is no telling where the price can go.....and many will look back at .01/shr and regret not buying more stock......Keep in mind that 85% of the stock is insider held and restricted ,,,,cannot be sold into the market.

M ,,Can you post todays PR here? K

MM's will not buy the many millions of shares of TCLN or any PK sheet or BB stock that someone is dumping on the market .....It will not happen.....MM's will buy and sell enough shares to make a market but that's it.

The seller/sellers are not insiders in Quture. Keep in mind there are million share buyers for those selling million share blocks. Very likely the buyers are very close to what's going on within Quture and are very comfortable picking up those millions of shares. I was told the seller was cleaned out ....but obviously there may be more shares. MarketMakers do not buy stock ...Some folks out there have bought millions of shares in the last 2 or 3 months.

TCLN as a development stage company attracts stock buyers willing to have some faith and take a risk. Once the contracts and revenue start coming in the attraction extends to a far larger number of stock buyers. Getting the word out will take some time but the sellers are now gone(there will be profit takers along the way). Also once the stock price gets into double digits and the dollar range a whole new population of buyers come into play ....And if the story plays out as the company has presented itself, the funds/institutions will be looking at Quture.

The buying should come with the first sign of a hospital contract and that monthly revenue stream..

IMO, It's trading on no news ......What I'm hearing is things are ramping up really well ,,as in fast paced right now,, Constellation is now locating an office in Florida where Quture is located. This suggests Jens expects to be very busy with Quture this year ,,,IMO.

There is obviously a big buyer for all that stock ....He just put another 300K shares on the bid .....Buying 2.3M shares already today

Smartmetric had won on 'contact' cards earlier and the March 5 hearing was on 'contactless' card appeal ,,,that much smaller piece of the business ,,, and this hearing now releases the entire case for trial on damages or a settlement ........As I understand it.

Note: Also in today's PR ...Intersystems Conference which TCLN will attend in Florida .....

http://www.intersystems.com/summit2012/index.html

In order to trade near 5M shares of TCLN in one day without changing the stock price somebody wants this stock. We know there is a shell owner wanting to sell his stock. How many shares are left? ...I wish I knew. But the end must be near ...

I'm told the selling stockholder should be finished off today .....Time will tell

Got my Sample Pack from the ForeverGreen exec I talked with last week.....Very good quality items. This company seems to be getting the job done ....A good hold for this year

All news is being held up while Quture management is getting the selling stockholder(the TCLN shell owner) to sell them their stock. They do not want this seller to sell into any news they put out....There is some great news to put out I'm told and the Quture management could probably buy up all the stock with their pocket change ...I'm looking every day myself ....

Talked with the company yesterday ....
None of the past years growth is in the stock price IMO...Good conversation ....They are sending me a sample pack ....I'll add on any weakness ....I don't expect any though.

As I understand it:The supply being sold originates from the Shell owners of stock ...Specifically the owner of TCLN in it's prior life pre reverse merger. The Quture execs know this person and are wanting to buyout all his stock at one time ...When that happens only they know ....but I expect it within days ....The volume now may just be part of that buyout.

Add to that ....Quture was also in that same booth ....seen meeting with Ratheon execs ...I've been told.

The HIMSS Conference is going on this week ...
This brings all the players in Hospital and Health care management into one place to look at new technologies .....Quture/Intersystems gets it's time on display ...
InterSystems Platform

Medical Proctoring Product on Leading Technology Platform to Be Available in Early 2012; Marketing to Target Over 5000 Hospitals With Potential $500,000,000 US Market
MarketwirePress Release: Techs Loanstar, Inc. – Tue, Dec 20, 2011 7:00 AM EST

WEST PALM BEACH, FL--(Marketwire -12/20/11)- Techs Loanstar, Inc. (OTCQB: TCLN.PK - News) (Pinksheets: TCLN.PK - News) and Quture, Inc. ("Quture") are aggressively preparing to release the first commercial component of their new product line. Quture's new "transformative" performance measurement tool will introduce electronic performance measurement on the InterSystems Corporation (www.InterSystems.com) technology platform. This application will be used to electronically "proctor" the clinical performance of physicians and practitioners for current clinical proficiency and competence to use medical devices and perform specific clinical interventions, and procedures.

Proctoring is a process for peers to assess the clinical capability of physicians and practitioners to use new clinical procedures, either new for them or when they are new to a hospital or surgery center. Proctoring is mandated by the Joint Commission as a published and required standard to be accredited and receive federal funds from Medicare or Medicaid. Until now, physicians have reviewed medical records, used direct observation, simulation, and interviews to assess the competence of their peers to satisfy this mandate.

The Application Partnership Agreement with InterSystems is now the focus of a series of Demonstration Projects for new commercial product applications at hospitals throughout the United States. Keith Candiotti, M.D., continues to lead the development of this application. He now serves as Vice Chair of Clinical Research, Department of Anesthesiology, Jackson Memorial Hospital and University of Miami Miller School of Medicine. As the former director of the training and residency program, Dr. Candiotti is uniquely qualified to guide the science of measuring clinical performance in the required ACGME framework. The extensive intellectual property of Quture is embedded in the Company's clinical performance measurement product on the InterSystems platform. InterSystems and Quture hope to soon jointly announce the success of a series of Demonstrations after its application with selected performance and outcomes measures to electronically measure clinical performance of new medical procedures or by physicians for the first time to credentialing medical practitioners. The Demonstrations will prove the use of electronic data integration and analytics to transform existing labor-intensive, anecdotal, and vital quality and risk management processes to rapid, enterprise-wide electronic processes.

"This is another big step forward in our development," said Landon Feazell, CEO of Quture. "The collaboration between Dr. Candiotti and Dr. Janice J. Ophoven, as previously announced, in using the incredible technology platform of InterSystems is a significant milestone. Our first component will be commercially available in early 2012, and this product is a key component for hospitals to electronically and scientifically achieve the mandate of the Joint Commission. Our marketing will be targeting over 5000 hospitals with an aggregate marketing potential of $500,000,000." The global market will be the next target for our new proctoring application.

InterSystems' interface engine Ensemble® will be used for data integration to capture clinical data from any vendor's electronic medical records and software into the InterSystems CACHÉ® (http://www.intersystems.com/cache/index.html) object-oriented database. The InterSystems platform is aptly-suited to harness and support the power of Quture's intellectual property. Additionally, InterSystems' DeepSee™ dashboard for embedded real-time business intelligence and Zen report writer complete the platform package for health care enterprise management that is so desperately needed by physicians, clinicians, administration, boards and the quality and patient safety professionals in hospitals and physician groups in America and internationally.

Added Feazell: "It is truly remarkable that InterSystems' technology platform is fully developed and deployed to satisfy our requirements and specifications. We believe we can solve the problems of disparate databases and silos of information that have limited our endeavors for over 35 years of clinical performance measurement in health care. This is a pivotal juncture in health care and its impact on the American economy and on the lives of patients and the professionals devoted to caring for them. We will be proud to introduce these new tools to accomplish our mission and to exceed and bring new capability to the extensive new federal and national mandates and standards."

THE LINK:
http://onlinebuyersguide.himss.org/profile.asp?VendorId=7301&F_SearchType=Key&F_SearchCriteria=intersystems&F_Country=&F_State=&F_CategoryId=&F_City=&F_Zip=#conf11

New PR ...The deals Keep Coming ....
Bulova Technologies Group, Inc. and Tri Gas Oil and Trade S.A. sign Agreement, with ITF Enhancing Human Security
Business WirePress Release: Bulova Technologies Group, Inc. – 6 hours ago


CLEARWATER, Fla.--(BUSINESS WIRE)--

Bulova Technologies Group, Inc. (OTCQB:BLVT.PK - News) (the “Company”) and Tri Gas Oil And Trade S.A. (“TGT”) announced today the signing of an agreement with ITF Enhancing Human Security (formerly the International Trust Fund to Enhance Human Security) (“ITF”), the world’s leading military mine removal advocacy organization, to create a team for demilitarization (removal and destruction) of mines and other explosive devices around the globe.

ITF was established by the Government of Slovenia in March 1998 to raise funds, provide services and manage mine action projects. The European Commission acknowledged ITF as the reference model of regional organization in mine action. Since the inception of ITF, over 100 donors have made donations to ITF for mine action activities. Almost 95% of the donations originate from public donors-including 27 governments, the European Union (EU) and the United Nations Development Program (UNDP), and many local authorities. For more information, please visit their website at http://www.itf-fund.si/

Stephen L. Gurba, President and CEO of the Company stated, “This agreement will allow us access to funding sources provided by international donors for the mine demilitarization process employed by ITF and accelerate the expansion of our Mortar Exchange Program

A Good Revenue Source for Bulova
Bulova becomes middle man in delivering munitions ...requires little in financing a can deliver very large orders ...

Weapons Supply to Afghanistan
Business WirePress Release: Bulova Technologies Group, Inc. – Wed, Feb 15, 2012 8:30 AM EST


Bulova Technologies Group, Inc.


CLEARWATER, Fla.--(BUSINESS WIRE)--

Bulova Technologies Group, Inc. (OTCQB:BLVT.PK - News) (the “Company”) recently announced that Bulova Technologies Ordnance Systems LLC (“BTOS”) received an award for $4.8 million under the US Army IDIQ Non-Standard Weapons BPA to supply weapons to Afghanistan. These weapons will be provided by Rosoboronexport (“ROE”) in Russia and will be delivered to Afghanistan in the Company’s third quarter.

As announced previously in our press release dated February 9, 2012, the Company has partnered with ROE to supply Non-Standard Weapons and Non-Standard Ammunition under contract with the US Army for Afghanistan and Iraq. For more information on ROE, please visit their website at www.roe.ru.

At the first sign of a money making contract this stock soars as it becomes conformation of the business plan ....AND buying stock at this less than .02 or .03 will be the end of that bargain .....IMO, this should be bought to the max you can handle at this price ....PR's could be coming very soon ....

I've been told that 2B shares are restricted ...and when released for sale, shareholders can only sell 1% per year in the next 20 years. Basically that means to me that the big holders/owners of this company plan to sell the entire company to a bigger player ,,,maybe Intersystems(TCLN's partner) in the next few years ...They see no need to sell their shares any sooner.

Just Who is ROSOBORONEXPORT?
It's just the Largest Arms dealer in Russia ...Which likely makes it the Largest in the World ..

Rosoboronexport:

Accounts for more than 90% of Russia's annual arms sales.
Represents intellectual and production potential of Russian Defense Industrial Complex consisting of more than 1500 research institutes, design bureaus and manufacturing plants.
Has cooperated with more than 60 countries during its 50-year history.
Central headquarters in Moscow, representative offices in 44 foreign countries and in 26 major industrial regions in Russia.

Basic Trade Activities

Export/import of military/dual use equipment and strategic raw materials.
Logistics and maintenance, delivery of spare parts, tools and accessories, special liquids, fuels and lubricants required for proper operation of the supplied material.
Technical assistance in construction of defense infrastructure, including arms manufacturing plants, airfields, depots, firing ranges, training centers, etc.
Delivery of material, components, and parts for licensed arms production.
Retrofits, upgrades and modernization of previously supplied weapon systems.
Training of personnel in Russia and at Customer's facilities.
Promotion of civil-purpose innovative technologies developed by the Russian defense industries.

News,, More Good Stuff Today
Bulova Technologies Group, Inc. Partners with Joint Stock Company Rosoboronexport

CLEARWATER, Fla.--(BUSINESS WIRE)--

Bulova Technologies Group, Inc. (OTCQB:BLVT.PK - News) (the “Company”) announced today the conclusion of a strategic partnership with Joint Stock Company Rosoboronexport, a company established under the laws of the Russian Federation to carry out foreign trade activity for military products.

Bulova Technologies Group, Inc., and Rosoboronexport will work together under this partnership to provide products pursuant to the Company’s Blanket Purchase Agreements with the U.S. Government for Non-Standard Weapons and Non-Standard Ammunition, as well as to other approved customers.

With the assistance of Rosoboronexport, the Company has also secured financing through Novikombank, a Russian Bank, to fund contracts that require Russian supplied ammunition and weapons.

President and CEO Stephen L. Gurba stated, “This strategic partnership provides an unprecedented opportunity for Bulova Technologies Group, Inc., to win future Non-Standard Ammunition and Weapons contracts with the U.S. Government as well as to secure the necessary financing to fulfill these orders.”